The Polish Society of Gynecological Oncology Guidelines for the Diagnosis and Treatment of Cervical Cancer (v2024.0)
Authors:
- Jacek J. SznurkowskiJSJacek J. Sznurkowski
- Lubomir BodnarLBLubomir Bodnar
- Łukasz SzylbergŁSŁukasz Szylberg
- Agnieszka Zołciak-SiwinskaAZAgnieszka Zołciak-Siwinska
- Anna Dańska-BidzińskaADAnna Dańska-Bidzińska
- Dagmara Klasa-MazurkiewiczDKDagmara Klasa-Mazurkiewicz
- Agnieszka RychlikARAgnieszka Rychlik
- Artur KowalikAKArtur Kowalik
- Joanna StrebJSJoanna Streb
- Mariusz BidzińskiMBMariusz Bidziński
- Włodzimierz SawickiWSWłodzimierz Sawicki
Open Access
- 25 July 2024
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (15) , 4351
Abstract
Background: Recent publications underscore the need for updated recommendations addressing less radical surgery for <2 cm tumors, induction chemotherapy, or immunotherapy for locally advanced stages of cervical cancer, as well as for the systemic therapy for recurrent or metastatic cervical cancer. Aim: To summarize the current evidence for the diagnosis, treatment, and follow-up of cervical cancer and provide evidence-based clinical practice recommendations. Methods: Developed according to AGREE II standards, the guidelines classify scientific evidence based on the Agency for Health Technology Assessment and Tariff System criteria. Recommendations are graded by evidence strength and consensus level from the development group. Key Results: (1) Early-Stage Cancer: Stromal invasion and lymphovascular space involvement (LVSI) from pretreatment biopsy identify candidates for surgery, particularly for simple hysterectomy. (2) Surgical Approach: Minimally invasive surgery is not recommended, except for T1A, LVSI-negative tumors, due to a reduction in life expectancy. (3) Locally Advanced Cancer: concurrent chemoradiation (CCRT) followed by brachytherapy (BRT) is the cornerstone treatment. Low-risk patients (fewer than two metastatic nodes or FIGO IB2-II) may consider induction chemotherapy (ICT) followed by CCRT and BRT after 7 days. High-risk patients (two or more metastatic nodes or FIGO IIIA, IIIB, and IVA) benefit from pembrolizumab with CCRT and maintenance therapy. (4) Metastatic, Persistent, and Recurrent Cancer: A PD-L1 status from pretreatment biopsy identifies candidates for Pembrolizumab with available systemic treatment, while triplet therapy (Atezolizumab/Bevacizumab/chemotherapy) becomes a PD-L1-independent option. Conclusions: These evidence-based guidelines aim to improve clinical outcomes through precise treatment strategies based on individual risk factors, predictors, and disease stages.Keywords
This publication has 133 references indexed in Scilit:
- Test Performance of Cervical Cytology Among Adults With vs Without Human Papillomavirus VaccinationJAMA Network Open, 2022
- Effectiveness of Sequential Chemoradiation vs Concurrent Chemoradiation or Radiation Alone in Adjuvant Treatment After Hysterectomy for Cervical CancerJAMA Oncology, 2021
- Survival After Minimally Invasive vs Open Radical Hysterectomy for Early-Stage Cervical CancerJAMA Oncology, 2020
- Screening for Cervical Cancer With High-Risk Human Papillomavirus TestingJAMA, 2018
- Cytology versus HPV testing for cervical cancer screening in the general populationCochrane Database of Systematic Reviews, 2017
- Hysterectomy with radiotherapy or chemotherapy or both for women with locally advanced cervical cancerCochrane Database of Systematic Reviews, 2015
- Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysisCochrane Database of Systematic Reviews, 2010
- Comparison of Liquid-Based Cytology With Conventional Cytology for Detection of Cervical Cancer PrecursorsJAMA, 2009
- Prognostic factors of early stage cervical cancer treated by radical hysterectomyCancer, 1995
- Prophylactic Extended-Field Irradiation of Para-aortic Lymph Nodes in Stages IIB and Bulky IB and IIA Cervical CarcinomasJAMA, 1995